Position in ERAS
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$601,940
+$118,498 QoQ
Shares Held
32,857
+10.0% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#153
of 255 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Marks Group Wealth Management, Inc holds $6,508,451 across 8 Biotechnology names. ERAS ranks #5 (9.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CYTK |
Cytokinetics Inc
|
18,024 | $1,535,464 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
9,088 | $1,206,250 | |
| 3 | ASND |
Ascendis Pharma A/S
|
4,345 | $1,158,898 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,717 | $817,898 | |
| 5 | ERAS |
Erasca, Inc.
This page
|
32,857 | $601,940 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
4,422 | $507,070 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
7,224 | $419,931 | |
| 8 | FTRE |
Fortrea Holdings Inc.
|
15,000 | $261,000 |
All Filings in ERAS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $601,940 | 32,857 | Shares | Other | 2026-07-28 | |
| 2026-03-31 | $483,442 | 29,879 | Shares | Other | 2026-05-05 | |
| No filing history on record for this holder in this stock. | ||||||